Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Francisco Navarrete, María S. García‐Gutiérrez, Rosa Jurado‐Barba, Gabriel Rubio, Ani Gasparyan, Amaya Austrich-Olivares, Jorge Manzanares
Abstract
anorexia and bulimia nervosa). On the other hand, recent results reveal the potential therapeutic action of the endocannabinoid tone manipulation by inhibition of eCBs degrading enzymes, as well as by the modulation of cannabinoid receptor 2 (CB2r) activity on anxiolytic, antidepressive, or antipsychotic associated effects. Further clinical research studies are needed; however, current evidence suggests that the components of the ECS may become promising biomarkers in psychiatry to improve, at least in part, the diagnosis and pharmacological treatment of psychiatric disorders.
Topics & Concepts
Endocannabinoid systemSchizophrenia (object-oriented programming)Bulimia nervosaCannabinoid receptorMood disordersNeuroscienceAnxiolyticCannabinoidAnxietyNeuroimagingMedicinePsychologyBipolar disorderNeuropsychopharmacologyCannabinoid Receptor AgonistsPsychiatryEating disordersBiomarkerNeurochemistryCognitionNeurologyReceptorInternal medicineBiologyAgonistBiochemistryCannabis and Cannabinoid ResearchNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior